Tharimmune Stock Soars 46.8% on Promising Drug Results

On August 21, 2025, Tharimmune's stock surged by 46.8% in pre-market trading, marking a significant rise in investor interest and confidence in the company's prospects.

Tharimmune, a clinical-stage biotech firm, has been making headlines with its lead clinical candidate, TH104. The company recently announced positive simulation results for TH104, an experimental drug designed to prevent the effects of fentanyl and other strong opioids. The results suggest that TH104 could start working within 30 minutes and provide protection for about 24 hours, a significant advantage over current treatments like naloxone, which typically offer protection for only 30–90 minutes.

TH104's potential as a preventive treatment for military personnel and first responders who might be exposed to powerful opioids, including weaponized fentanyl, has also garnered attention. The urgent need for treatments that can be given in advance to protect people from the rapid effects of these drugs on breathing and the nervous system has highlighted the importance of Tharimmune's research.

Tharimmune's stock has seen significant volatility, with shares trading between $0.95 and $6.39 over the past 52 weeks. The company's focus on developing treatments for inflammatory and immune-related conditions, along with its innovative approach to addressing the opioid crisis, has positioned it as a key player in the biotech industry.